Dengue Fever Vaccine-various aspects-
There are two authorized dengue vaccines, Dengvaxia (CYD-TDV) and Qdenga (TAK-003), which provide protection against all four serotypes of the dengue virus, but they are not presently accessible in India.
Here’s a more thorough breakdown:
Dengue Vaccines:
Created by Sanofi Pasteur.
Licensed by the U. S. Food and Drug Administration and advised for regular use by the Advisory Committee on Immunization Practices.
Designed for children and adolescents aged 9–16 years who have confirmed past dengue virus infection and reside in regions where dengue is endemic.
Requires three doses, administered 6 months apart.
The manufacturer is halting the production of the vaccine due to insufficient global market demand to sustain its production.
Qdenga (TAK-003):
Developed by Takeda.
A live-attenuated vaccine comprising weakened forms of dengue virus serotypes 1, 2, 3, and 4.
Indicated for dengue disease prevention in those aged 4 and older, according to official guidelines.
Offers protection against fever and hospitalization resulting from dengue disease caused by any of the four dengue virus serotypes.
Butantan-DV:
Another live-attenuated tetravalent dengue vaccine.
Important Considerations:
No Specific Dengue Treatment: There is no specific antiviral treatment available for dengue fever.
Prevention: The most effective way to avoid dengue fever is to prevent mosquito bites.
Dengue-Endemic Areas: Dengue fever is prevalent in numerous tropical and subtropical regions, including certain areas of South and Southeast Asia, Latin America, and Africa.
Travel Precautions: If traveling to a dengue-endemic region, take steps to prevent mosquito bites, such as wearing long sleeves, applying insect repellent, and staying in well-screened or air-conditioned accommodations.
Vaccination: Speak with your healthcare provider to assess if a dengue vaccine is suitable for you, particularly if you live in or plan to travel to a dengue-endemic area.
Current Situation in India: Although there are no licensed vaccines available in India, ICMR and Panacea Biotec have started the first Phase 3 clinical trial for a dengue vaccine.
If Any Patient of ENT Requires Any Surgery, Opd Consultation Or Online Consultation In Clinic of ENT Specialist Doctor Dr. Sagar Rajkuwar ,He May Contact Him At The Following Address-
Prabha ENT Clinic, Plot no 345,Saigram Colony, Opposite Indoline Furniture Ambad Link Road ,Ambad ,1 km From Pathardi Phata Nashik ,422010 ,Maharashtra, India-Dr. Sagar Rajkuwar (MS-ENT), Cell No- 7387590194, 9892596635
About a Dengue Vaccine
A dengue vaccine offers your child reliable, efficient, and enduring defense against dengue sickness, hospital admission, and severe conditions.
Children must undergo testing to verify any prior dengue infection before receiving the vaccine.
For complete protection, three doses of the vaccine are necessary.
Consult with your child’s healthcare provider to determine if your child qualifies for a dengue vaccine.
Notice regarding Dengvaxia
Sanofi-Pasteur will cease the production of its dengue vaccine for children. The producer is halting the vaccine due to insufficient demand in the worldwide market to sustain its production. The CDC, working with the Puerto Rico Department of Health, will keep informing health professionals about the cessation of Dengvaxia and the recommended use of this vaccine by the Advisory Committee on Immunization Practices (ACIP). Dengvaxia is effective and safe when given as advised. There are two additional dengue vaccines either authorized or in advanced stages of development. Nonetheless, these are not presently accessible in the United States. Individuals can continue to safeguard themselves and their families from dengue by avoiding mosquito bites and managing mosquitoes in and around their residences.
Overview
Dengvaxia is the sole dengue vaccine presently accessible in the United States.
Dengvaxia is advised to avert dengue in youngsters aged 9–16 years, who have a laboratory-confirmed prior dengue virus infection and reside in regions where dengue is prevalent.
Dengue is prevalent in the U. S. territories of American Samoa, Puerto Rico, and the U. S. Virgin Islands, as well as in the freely associated states, which include the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.
For update on further important health related topics and frequently asked questions on health topics by general population please click on the link given below to join our WhatsApp group –
https://chat.whatsapp.com/Lv3NbcguOBS5ow6X9DpMMA
Test prior to vaccination
Laboratory verification of a past dengue infection is necessary for vaccination with Dengvaxia.
Testing prior to vaccination will verify that your child has experienced dengue previously.
In children who have not previously contracted dengue, the dengue vaccine heightens the risk of hospitalization and severe illness if the child contracts dengue after vaccination.
To decrease the risk of vaccinating children who have never experienced dengue, a blood test can determine the presence of a previous dengue infection.
If the test result is affirmative, your child can receive the vaccine.
If the test result is negative, your child will not be eligible for vaccination. Your child should undergo testing again in one or two years.
Types of testing
Your child’s healthcare provider will request a blood test to verify a prior dengue infection. The healthcare provider will request a test that has received approval from the local or territorial health department.
OR
If your child experienced a prior dengue illness that was validated by a specific kind of laboratory test, your child might not require another blood test.
Three doses required
Dose 1 may be administered after verifying that your child had a previous dengue infection.
Dose 2 is administered 6 months following the first dose.
Dose 3 is given 6 months after the second dose.
Safety and efficacy
The dengue vaccine offers protection against all four varieties of dengue.
The vaccine is both safe and effective for children who have had dengue before.
The vaccine has minimal side effects.
The most frequently occurring side effects include tenderness, itchiness, or pain at the injection site, headaches, fatigue, and overall discomfort.
These side effects are typical indications that the body is developing immunity, and they should resolve within a few days.
Special populations
Pregnancy
Pregnant individuals were not specifically included and examined in the vaccine trials. While no notable differences in negative pregnancy results between vaccinated and unvaccinated individuals were identified, the number of pregnant individuals enrolled was insufficient to assess the impact of Dengvaxia on pregnancy.
Is there a vaccine for dengue fever?
Dengvaxia is the sole dengue vaccine presently accessible in the United States. Dengvaxia is advised for preventing dengue in children between the ages of 9 and 16 years, who have a laboratory-confirmed history of dengue virus infection and reside in regions where dengue is prevalent.
How long before travel should you get dengue fever vaccine?
The vaccine provides strong protection after the initial dose, which needs to be administered at least 2 weeks prior to departure. Keep in mind that obtaining the second dose before your upcoming trip to another dengue-endemic area is crucial.
The purpose of dengue fever vaccinations is to protect against infection from the dengue virus, which is transmitted by mosquitoes. Dengvaxia is the most widely used dengue vaccine. It is advised for youngsters and adolescents who reside in dengue-prone regions and have previously tested positive for the illness in a lab.
A closer look:
Dengvaxia:
Children and teenagers between the ages of 9 and 16 who have previously contracted dengue and reside in regions with a high prevalence of the disease are specifically advised to get this vaccination. The treatment consists of three doses given over the course of a year, with the second dose given six months after the first and the third dose given six months after the second.
Eligibility:
The CDC states that children and teenagers who have previously contracted dengue virus and reside in regions with a high dengue incidence are especially advised to use Dengvaxia. The World Health Organization (WHO) states that Qdenga is safe for a larger population, including those who have never contracted dengue fever.
Safety and Efficacy:
When given as directed, Dengvaxia is thought to be both safe and efficient. According to research, Dengvaxia can prevent dengue sickness in 80% of children who previously had dengue. Additionally, Qdenga has demonstrated encouraging clinical trial outcomes, with studies demonstrating significant protection against dengue infection and severe illness.
Recommendations:
The CDC advises using Dengvaxia for youngsters and teenagers in particular regions where dengue is common. Qdenga is recommended by the WHO for usage in places where there is a high burden and transmission intensity of dengue fever.
Adverse Reactions:
Headache, muscle discomfort, exhaustion, low-grade fever, and injection site pain are some of the frequent adverse effects of dengue vaccines.
Essential Factors:
vaccination as one component of a comprehensive strategy:
Vaccination, vector control strategies (managing mosquito populations), and public health education should all be part of dengue prevention.
Travelers:
Travelers to dengue-prone areas should speak with their healthcare practitioner about vaccine and preventative strategies.
See a doctor:
Particularly if you have a history of dengue or are going to a place where it’s prevalent, it’s important to speak with a healthcare provider to see whether a dengue vaccine is right for you or your child.
The Illness at a Glance
The second most frequent fever cause in sick foreign tourists is dengue. This is brought on by infection from the dengue virus.
The bite of infected mosquitoes transmits the dengue virus. The white stripes on their legs can be used to identify the typically Aedes aegypti mosquito species. They mostly bite throughout the day.
With cases in over 120 countries, dengue fever is common throughout the tropics and subtropics.
- It is believed that there are about 100 million instances of dengue disease each year.
- Infants and children who reside in tropical and subtropical regions are most at risk from serious illnesses.
- Dengue outbreaks are frequent and often follow a seasonal trend.
- Southern Europe has seen outbreaks caused by imported infection.
The Disease
The majority of dengue infections either cause no symptoms or only minor ones.
- A sudden onset of fever, headache, and muscular and joint discomfort may happen between 4 and 10
- days following the mosquito bite. Additionally, a rash can appear.
In most cases, the condition improves over a few days to a week, and major consequences are rare.
Dengue fever can advance to a more severe and potentially deadly illness known as severe dengue in 1-2% of cases.
Treatment
Although there is no particular course of treatment for dengue, those who experience symptoms should seek medical advice.
- Over-the-counter medications like paracetamol, sufficient rest, and adequate hydration can often alleviate minor symptoms like headache and fever at home.
- In the event of severe illness or complications, hospitalization may be necessary.
How to stop dengue
You should think about not visiting nations where dengue is prevalent if you have a higher risk of developing a severe form of the disease.
Those who are at risk include those who:
- are quite young
- are older
- are expecting
- have a compromised immune system
- have a variety of medical issues, such as asthma, diabetes, hypertension, or a condition that increases your bleeding tendency.
- Previously experienced dengue
The best way to prevent dengue fever if you live in a nation where it exists is to stay away from mosquito bites.
Click on the link below to learn more about this disease.
FOR INFORMATION IN GREAT DETAIL ON Dengue Fever Treatments PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.
FOR INFORMATION IN GREAT DETAIL ON Dengue Fever Symptoms PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.
FOR INFORMATION IN GREAT DETAIL ON 7 Warning Signs Of Dengue Fever PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.
FOR INFORMATION IN GREAT DETAIL ON Dengue Breakbone Fever PL CLICK ON THE LINK GIVEN BELOW-It Is Always Better To View Links From Laptop/Desktop Rather Than Mobile Phone As They May Not Be Seen From Mobile Phone. ,In Case Of Technical Difficulties You Need To Copy Paste This Link In Google Search. In Case If You Are Viewing This Blog From Mobile Phone You Need To Click On The Three Dots On The Right Upper Corner Of Your Mobile Screen And ENABLE DESKTOP VERSION.
If Any Patient of ENT Requires Any Surgery, Opd Consultation Or Online Consultation In Clinic of ENT Specialist Doctor Dr. Sagar Rajkuwar ,He May Contact Him At The Following Address-
Prabha ENT Clinic, Plot no 345,Saigram Colony, Opposite Indoline Furniture Ambad Link Road ,Ambad ,1 km From Pathardi Phata Nashik ,422010 ,Maharashtra, India-Dr. Sagar Rajkuwar (MS-ENT), Cell No- 7387590194, 9892596635
Issued in public interest by –
www.entspecialistinnashik.com
